• Mashup Score: 0

    By: Allen Wilbanks Date: October 03, 2023 Julie Vose, MD, a respected expert in the field of lymphoma, began her presentation by acknowledging the challenging nature of mantle cell lymphoma and introduced herself with the following quote: Thank you very much. So it’s my pleasure to talk about mantle cell lymphoma, a…

    Tweet Tweets with this article
    • Dive into the latest insights on Mantle Cell Lymphoma with Julie Vose, MD @NebraskaDoctors. Discover key aspects of diagnosis, treatment, and the evolving landscape of this condition. [slides][video]https://t.co/p1hvcKH7lD #MantleCellLymphoma @MDEducation @Ryan_Fitzpatric https://t.co/iTPgzpqEL0

  • Mashup Score: 0
    article - 6 month(s) ago

    INTRODUCTIONNon-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of lymphoid malignancies that originate from B cells, T cells, or natural killer cells. There are 70 different types of NHL as per the 2016 WHO Classification.[1] Among them, Mantle cell lymphoma (MCL) is one of the rarest varieties, comprising only 6% of NHL.[2] It is more common in males than females (M: F is 4:1 as in 2015)….

    Tweet Tweets with this article
    • #MantleCellLymphoma (MCL) accounts for less than 1% of head and neck malignancies. Due to its short clinical course, there are limited data on standard treatment protocols. Even with the present treatments, only 30% of patients achieve complete response. https://t.co/f3elQocnEu https://t.co/WTxfwtsYJE

  • Mashup Score: 1

    By Mikaela McCabe, PharmDWhat is pirtobrutinib?Pirtobrutinib is a reversible Bruton tyrosine kinase (BTK) inhibitor that blocks signaling of B-cell antigen receptor and cytokine pathway signaling protein, which are essential for B-cell proliferation and functionality. Pirtobrutinib binds to both wild-type BTK and BTK with C481 mutations. What is pirtobrutinib approved for?Pirtobrutinib is…

    Tweet Tweets with this article
    • Pirtobrutinib is approved for the treatment of #MantleCellLymphoma. Overall, 50% had a response to pirtobrutinib 200 mg once daily, with 13% having a complete response and 38% having a partial response. https://t.co/n9sB66X1Fi #BloodCancerMonth https://t.co/YtokYUH8en

  • Mashup Score: 0
    article - 6 month(s) ago

    INTRODUCTIONMantle cell lymphoma (MCL) is a B-cell malignancy mainly diagnosed in the elderly population, and more commonly among males. It is among the more recently defined forms of B-cell lymphomas, when the association between centrocytic morphology and the presence of a translocation t(11;14) was made in the 1990s,1 defining what is now classified as MCL.Since then, the lymphoma community…

    Tweet Tweets with this article
    • #MantleCellLymphoma (MCL) is a B-cell malignancy currently considered incurable. Although some patients obtain prolonged remission after first-line #chemoimmunotherapy, many will need several treatment lines. Read more: https://t.co/dwgteK8Mnk #ThisIsBloodCancer #Lymphoma https://t.co/c9oG4UsrEl

  • Mashup Score: 0
    article - 6 month(s) ago

    1. IntroductionBullous pemphigoid is an autoimmune subepidermal blistering disorder. Mantle cell lymphoma is a B-cell malignancy of a rare type of non-Hodgkin lymphoma. Bullous pemphigoid associated with mantle cell lymphoma is even rarer which may suggest a paraneoplastic phenomenon.[1]2. Case reportA 29-year-old Malay man, a federal plantation supervisor, was admitted with 5 months’ history of…

    Tweet Tweets with this article
    • #BullousPemphigoid, an autoimmune subepidermal blistering disorder, associated with #MantleCellLymphoma, a rare type of non-Hodgkin lymphoma, may suggest a paraneoplastic phenomenon. Read more: https://t.co/qxQdWEHKax #ThisIsBloodCancer #Lymphoma https://t.co/2WHpU77CpP

  • Mashup Score: 0
    article - 6 month(s) ago

    INTRODUCTIONNon-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of lymphoid malignancies that originate from B cells, T cells, or natural killer cells. There are 70 different types of NHL as per the 2016 WHO Classification.[1] Among them, Mantle cell lymphoma (MCL) is one of the rarest varieties, comprising only 6% of NHL.[2] It is more common in males than females (M: F is 4:1 as in 2015)….

    Tweet Tweets with this article
    • #MantleCellLymphoma (MCL) accounts for less than 1% of head and neck malignancies. Due to its short clinical course, there are limited data on standard treatment protocols. Even with the present treatments, only 30% of patients achieve complete response. https://t.co/f3elQocnEu https://t.co/UTfqSP6gyS

  • Mashup Score: 0

    By Mikaela McCabe, PharmDWhat is pirtobrutinib?Pirtobrutinib is a reversible Bruton tyrosine kinase (BTK) inhibitor that blocks signaling of B-cell antigen receptor and cytokine pathway signaling protein, which are essential for B-cell proliferation and functionality. Pirtobrutinib binds to both wild-type BTK and BTK with C481 mutations. What is pirtobrutinib approved for?Pirtobrutinib is…

    Tweet Tweets with this article
    • Pirtobrutinib is a reversible BTK inhibitor that blocks B-cell antigen receptor signaling and cytokine pathway signaling protein. It is approved for adults with relapsed or refractory #MantleCellLymphoma after at least two lines of prior systemic therapy. https://t.co/hFisZm9n8n https://t.co/qVmn33gPvz